Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102480Source: DataRank Database

Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study is a dataset published in EClinicalMedicine (2024). On theSindex it has a DataRank of 0.440, placing it in the top 42.6% of the data-sharing corpus. It has been cited 11 times, with 7 citing works in its 1-hop citation network.

Top 43%percentile

0.440DataRank

Ranks in the top 43% for downstream scientific impact

Data paper Open Access11 citations · 7 citing works in its network

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)OA: goldTopics (7)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (1/3)

Dataset classification

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 85%Citation Network 15%

Base Score Contribution

0.373

From this paper's citation signal

Citation Network Contribution

0.0672

From 4 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 7 citers.

Real-world treatment outcomes for Hodgkin lymphoma in South Africa: a prospective observational study
Infectious Agents and Cancer20242 citations36 referencesContributes 0.031
Early-stage Hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes
BMC Cancer20252 citations37 referencesContributes 0.030
Clinicopathological features and prognostic factors of AIDS-related lymphoma: a retrospective single-center study in China
Annals of Hematology20251 citations62 referencesContributes 0.011
Advances in pharmacological activity and drug delivery systems of vinca alkaloids
Natural Product Research20251 citations90 referencesContributes 0.008
THE FIRST SUCCESSFUL EXPERIENCE OF HIGH-DOSE CHEMOTHERAPY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA IN A PATIENT WITH HIV INFECTION AT THE PIROGOV NATIONAL MEDICAL AND SURGICAL CENTER
Bulletin of Pirogov National Medical & Surgical Center20240 citations38 referencesContributes 0.000

Authors (13)

Evaristar Kudowa,Dalton M. Craven ORCID,Luke Eastburg ORCID,Maria Chikasema,Edwards Kasonkanji ORCID

Live enrichment

PubMed:38356728 PMC:PMC10864874

NCI NIH HHS

Grant: U54 CA190152

FIC NIH HHS

Grant: K01 TW011191

NCI NIH HHS

Grant: U54 CA254564

FIC NIH HHS

Grant: K01 TW011470

NCI NIH HHS

Grant: D43 CA260641

NCI NIH HHS

Grant: UM1 CA121947

FIC NIH HHS

Grant: D43 TW009340

National Institutes of Health

Grant: 1D43CA260641-01

Malawi Cancer Outcomes Research Program (M-CORP)

National Institutes of Health

Grant: 5U54CA190152-04

Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu

National Institutes of Health

Grant: 5K01TW011191-03

Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi

National Institutes of Health

Grant: 3UM1CA121947-19S9

Consortium for Advancing Management and Prevention of Cancer in People with HIV

National Institutes of Health

Grant: 5U54CA254564-03

Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa

National Institutes of Health

Grant: 1K01TW011470-01

Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi

National Institutes of Health

Grant: 3D43TW009340-11S9

UJMT LAUNCH: Training the next generation of leaders in global health research

National Cancer Institute

National Institutes of Health

goldLicense: cc-by-nc-nd

publisherhttp://www.thelancet.com/article/S2589537024000592/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2589537024000592?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2589537024000592?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10864874/pdf/main.pdf

repositoryhttps://doaj.org/article/94b788870e5a4755801c75ba9d06bdef

Keywords

HIVSub-Saharan AfricaCostHodgkin LymphomaAbvdMicrocostingArticles

Additional file 1 of Real-world treatment outcomes for Hodgkin lymphoma in South Africa: a prospective observational study

10.6084/m9.figshare.27123880.v1figshare

Additional file 1 of Real-world treatment outcomes for Hodgkin lymphoma in South Africa: a prospective observational study

10.6084/m9.figshare.27123880figshare